Reported 2 days ago
Tevogen Bio Holdings Inc. plans to expand the target population for its experimental drug, TVGN 489, to include patients aged 65 and older, amid rising COVID variant cases. This strategic move is expected to enhance the company's revenue forecasts, with anticipations of up to $22 billion in sales over five years. The medication, developed using the ExacTcell™ platform, specifically targets SARS-CoV-2 infections in immunocompromised patients and also addresses Long COVID.
Source: YAHOO